Berkshire Bank Grows Stock Position in Johnson & Johnson $JNJ

Berkshire Bank boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 22.5% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 31,088 shares of the company’s stock after buying an additional 5,711 shares during the period. Johnson & Johnson makes up approximately 1.1% of Berkshire Bank’s holdings, making the stock its 22nd largest holding. Berkshire Bank’s holdings in Johnson & Johnson were worth $4,749,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Krilogy Financial LLC raised its holdings in Johnson & Johnson by 20.4% during the 2nd quarter. Krilogy Financial LLC now owns 14,314 shares of the company’s stock valued at $2,186,000 after buying an additional 2,421 shares during the period. First Bank & Trust raised its holdings in Johnson & Johnson by 24.5% during the 2nd quarter. First Bank & Trust now owns 12,977 shares of the company’s stock valued at $1,982,000 after buying an additional 2,556 shares during the period. Triumph Capital Management raised its holdings in Johnson & Johnson by 27.2% during the 2nd quarter. Triumph Capital Management now owns 3,260 shares of the company’s stock valued at $498,000 after buying an additional 697 shares during the period. Silverberg Bernstein Capital Management LLC raised its holdings in Johnson & Johnson by 27.4% during the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 11,467 shares of the company’s stock valued at $1,752,000 after buying an additional 2,467 shares during the period. Finally, Bowman & Co S.C. raised its holdings in Johnson & Johnson by 6.7% during the 2nd quarter. Bowman & Co S.C. now owns 11,882 shares of the company’s stock valued at $1,815,000 after buying an additional 747 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $176.48 on Wednesday. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $181.16. The stock’s 50-day moving average is $171.67 and its 200 day moving average is $161.46. The company has a market cap of $425.02 billion, a P/E ratio of 18.87, a PEG ratio of 2.26 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter last year, the company earned $2.82 earnings per share. The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 55.61%.

Wall Street Analyst Weigh In

Several brokerages have commented on JNJ. UBS Group upped their price objective on Johnson & Johnson from $180.00 to $190.00 and gave the company a “buy” rating in a research report on Thursday, July 17th. Citigroup upped their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the company a “buy” rating in a research report on Thursday, August 21st. Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Guggenheim reaffirmed a “neutral” rating and issued a $167.00 price objective (up previously from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Finally, Morgan Stanley upped their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the company an “equal weight” rating in a research report on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $176.29.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.